TL Genomics Inc.

 +81-42316-1636
Contact

News

2020 / 07 / 20  17:56

TL Genomics grants exclusive license of fetal cell diagnosis in the territory of EU

TL Genomics has granted an exclusive license to a third-party company, regarding the fetal cell diagnosis patents and know-how. That company has invested in TL Genomics to collaboratively commercialize the technology.

 

 

 

 

2020 / 01 / 10  16:53

TL Genomics enters into business partnership with Fukoku Bussan Co., Ltd.

TL Genomics and Fukoku Bussan Co., Ltd. have collaboratively developed mass production technology of microfluidics chip. Now both companies recognize that the technology is ready for market, and agree that more close partnership will accelerate the business. Fukoku Bussan has invested in TL Genomics on Jan. 10, 2020, whose amount of investment is not disclosed.

 

[about Fukoku Bussan Co., Ltd.]

http://fukoku-jp.net/en/

 

2019 / 02 / 21  10:00

CEO Tomohiro Kubo wins Kyoto SMI Nakatsuji award in 2018

CEO Tomohiro Kubo wins 6th Kyoto SMI Nakatsuji award in 2018, for the development of microfluidics technology to enrich blood cells and its application on fetal cell isolation.

 

https://kyoto-smi.or.jp/?page_id=1617

2018 / 10 / 16  14:26

TL Genomics awarded Japanese government grants to accelerate R&D

TL Genomics will recieve about $0.7 million in government grants to help the company's mass production technology of microfluidics chip.

 

[about the government grantds]

- Startups in Corporate Alliance by NEDO (New Energy and Industrial Technology Development Organization)

 http://www.nedo.go.jp/koubo/CA2_100182.html

 

2018 / 05 / 07  13:05

TL Genomics Completes $3.0 Million Series B Financing

TL Genomics anounced the closing of a Series B financing. The company raised $3.0 million US, which was led by Nissei Captal nad also followed by SMBC venture capital and DBJ capital. This funding will support the company’s business and R&D world wide.

1 2
2020.11.29 Sunday